Overview

Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the Safety, Tolerability and Brain Function of 2 doses of PF-0254920 in Subjects with Early Huntington's Disease.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer